Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isentress

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

- PMLiVE

Novartis to make 15 drugs available at $1 a month

Comes after concerns surrounding hiked drug prices and effects on public health

- PMLiVE

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 

- PMLiVE

Bionor gears up for ‘kick and kill’ HIV data

Could also be used in conjunction with Celgene's cancer drug Revlimid

- PMLiVE

Hints of recovery at GSK as group sales climb

Drug revenue still falling but vaccines and HIV drugs help offset Advair decline

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

- PMLiVE

HIV vaccine from J&J starts human trials

Vaccine provided complete protection in primates for similar infection 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links